NCT04752358

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Adaptimmune · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the efficacy of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose esophageal or esophagogastric junction (EGJ) cancer expresses the MAGE-A4 protein.

Conditions

• Esophageal Cancer
• Esophagogastric Junction Cancer

Interventions

Type	Name	Description
GENETIC	Autologous genetically modified ADP-A2M4CD8 cells	Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1

Timeline

• Start date: 2021-09-15
• Primary completion: 2023-06-09
• Completion: 2023-12-15
• First posted: 2021-02-12
• Last updated: 2024-09-04
• Results posted: 2024-09-04

Locations

17 sites across 3 countries: United States, Canada, Spain

Regulatory

• FDA-regulated drug study